TY - JOUR
T1 - Beta-adrenergic receptor blockade in angiosarcoma
T2 - Which beta-blocker to choose?
AU - Embaby, Alaa
AU - van Merendonk, Lisanne
AU - Steeghs, Neeltje
AU - Beijnen, Jos
AU - Huitema, Alwin
N1 - Publisher Copyright:
Copyright © 2022 Embaby, van Merendonk, Steeghs, Beijnen and Huitema.
PY - 2022/9/15
Y1 - 2022/9/15
N2 - Beta-blockers are currently studied to improve therapeutic options for patients with angiosarcoma. However, most of these patients have no cardiovascular co-morbidity and it is therefore crucial to discuss the most optimal pharmacological properties of beta-blockers for this population. To maximize the possible effectiveness in angiosarcoma, the use of a non-selective beta-blocker is preferred based on in vitro data. To minimize the risk of cardiovascular adverse events a beta-blocker should ideally have intrinsic sympathomimetic activity or vasodilator effects, e.g. labetalol, pindolol or carvedilol. However, except for one case of carvedilol, only efficacy data of propranolol is available. In potential follow-up studies labetalol, pindolol or carvedilol can be considered to reduce the risk of cardiovascular adverse events.
AB - Beta-blockers are currently studied to improve therapeutic options for patients with angiosarcoma. However, most of these patients have no cardiovascular co-morbidity and it is therefore crucial to discuss the most optimal pharmacological properties of beta-blockers for this population. To maximize the possible effectiveness in angiosarcoma, the use of a non-selective beta-blocker is preferred based on in vitro data. To minimize the risk of cardiovascular adverse events a beta-blocker should ideally have intrinsic sympathomimetic activity or vasodilator effects, e.g. labetalol, pindolol or carvedilol. However, except for one case of carvedilol, only efficacy data of propranolol is available. In potential follow-up studies labetalol, pindolol or carvedilol can be considered to reduce the risk of cardiovascular adverse events.
KW - angiosarcoma
KW - beta-blockade
KW - drug repurposing
KW - pharmacological characteristics
KW - propranolol
UR - http://www.scopus.com/inward/record.url?scp=85139247738&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.940582
DO - 10.3389/fonc.2022.940582
M3 - Article
AN - SCOPUS:85139247738
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 940582
ER -